LMO2 as a Biomarker for Hypersensitivity to Genotoxic Therapy

Publication date: 16 September 2019Source: Cancer Cell, Volume 36, Issue 3Author(s): Claudio Scuoppo, Shan ZhaIn this issue of Cancer Cell, Parvin and colleagues identify the expression of LMO2 as a biomarker for DNA repair defects in lymphomas. Using isogenic cell lines and xenografts, the authors show that expression of LMO2 predicts sensitivity to PARP inhibition, especially in combination with genotoxic therapy.
Source: Cancer Cell - Category: Cancer & Oncology Source Type: research